We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Transfusion Practice Wastes Scarce Plasma

By LabMedica International staff writers
Posted on 30 Jul 2013
The use of a blood transfusion protocol in patients with severe trauma is feasible in hospitals, although it is associated with higher waste of plasma.

The protocol, in use since 2007, uses an equal ratio of red blood cells, plasma, and platelets to transfuse patients, yet this 1:1:1 ratio is associated with higher waste of donated blood plasma.

Scientists at the Sunnybrook Health Sciences Center (Toronto, ON, Canada) conducted a randomized trial to determine feasibility and safety of 1:1:1 ratio in 78 patients presenting in a large trauma center, with low blood pressure and substantial bleeding who were expected to need massive blood transfusion. More...
Forty patients were randomly assigned to the fixed-ratio transfusion, and the remaining 38 underwent the laboratory-guided transfusion protocol at the center.

Thawed type AB plasma, a scarce resource, is needed for 1:1:1 transfusion, which also involves delays because of the need to thaw the material. Deaths from all causes after 28 days was higher in the fixed-ratio group at 32.5% compared with 14% in the control group and there was a higher rate of respiratory distress in the patients receiving 1:1:1.


Sandro Rizoli, MD, PhD, a professor of surgery and senior author of the study, said, “These findings suggest that a fixed-ratio transfusion protocol is feasible, but it was associated with increased plasma wastage, about two units per patient”. Widespread adoption of the 1:1:1 strategy has significant resource and safety implications. Its full implementation requires access to thawed type AB plasma, which is chronically in short supply. The 1:1:1 transfusion protocol may lead to unnecessary exposure to blood components and an increased risk of acute respiratory distress syndrome, sepsis, and multiple organ dysfunctions.

The authors concluded that the randomized controlled trial showed the implementation of a fixed-ratio (1:1:1) transfusion protocol was feasible among patients with severe trauma. The full and widespread implementation of such a protocol will challenge blood suppliers because of the increased demand and wastage of plasma. Larger clinical trials are warranted to definitively evaluate the efficacy and safety of transfusion at a 1:1:1 ratio. The study was published on July 15, 2013, in the Canadian Medical Association Journal.

Related Links:
Sunnybrook Health Sciences Center



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.